BR0213581A - Uso de um inibidor de recaptação de norepinefrina seletivo - Google Patents

Uso de um inibidor de recaptação de norepinefrina seletivo

Info

Publication number
BR0213581A
BR0213581A BR0213581-7A BR0213581A BR0213581A BR 0213581 A BR0213581 A BR 0213581A BR 0213581 A BR0213581 A BR 0213581A BR 0213581 A BR0213581 A BR 0213581A
Authority
BR
Brazil
Prior art keywords
norepinephrine reuptake
reuptake inhibitor
selective norepinephrine
selective
cognitive impairment
Prior art date
Application number
BR0213581-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Franklin Porter Bymaster
Donald Richard Gehlert
David Lee Mckinzie
Charles Renkin Yang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0213581A publication Critical patent/BR0213581A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR0213581-7A 2001-12-11 2002-11-27 Uso de um inibidor de recaptação de norepinefrina seletivo BR0213581A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (1)

Publication Number Publication Date
BR0213581A true BR0213581A (pt) 2004-08-24

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213581-7A BR0213581A (pt) 2001-12-11 2002-11-27 Uso de um inibidor de recaptação de norepinefrina seletivo

Country Status (26)

Country Link
US (1) US20050009925A1 (enExample)
EP (1) EP1458368B1 (enExample)
JP (1) JP2005517647A (enExample)
KR (1) KR20040066895A (enExample)
CN (1) CN1713900A (enExample)
AU (1) AU2002352625A1 (enExample)
BR (1) BR0213581A (enExample)
CA (1) CA2467802A1 (enExample)
CO (1) CO5590907A2 (enExample)
CZ (1) CZ2004709A3 (enExample)
DE (1) DE60223718T2 (enExample)
EA (1) EA200400793A1 (enExample)
EC (1) ECSP045145A (enExample)
ES (1) ES2295435T3 (enExample)
HR (1) HRPK20040528B3 (enExample)
HU (1) HUP0402619A3 (enExample)
IL (1) IL161989A0 (enExample)
MX (1) MXPA04005716A (enExample)
MY (1) MY136367A (enExample)
NO (1) NO20042904L (enExample)
NZ (1) NZ532065A (enExample)
PL (1) PL369311A1 (enExample)
SK (1) SK2442004A3 (enExample)
TW (1) TW200300672A (enExample)
WO (1) WO2003049724A1 (enExample)
ZA (1) ZA200404274B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050049476A (ko) * 2002-08-14 2005-05-25 파마시아 앤드 업존 캄파니 엘엘씨 홍조를 치료하기 위한 레복세틴의 용도
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
US20070105960A1 (en) * 2003-08-27 2007-05-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
EA200601798A1 (ru) * 2004-04-30 2007-04-27 Уорнер-Ламберт Компани Ллс Замещенные соединения морфолина для лечения расстройств центральной нервной системы
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317731A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Hyperhidrosis treatment
WO2011014475A2 (en) * 2009-07-31 2011-02-03 National Taiwan University Treating negative symptoms of schizophrenia associated with defective neuregulin 1
WO2013051266A1 (ja) * 2011-10-03 2013-04-11 独立行政法人国立長寿医療研究センター タウ凝集阻害剤
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
WO2001001973A2 (en) * 1999-07-01 2001-01-11 Pharmacia & Upjohn Company Highly selective norepinephrine reuptake inhibitors and methods of using the same
HK1047577B (zh) * 1999-10-13 2005-09-16 辉瑞产品公司 用作一元胺重摄取抑制剂的联芳醚衍生物
WO2002053104A2 (en) * 2001-01-02 2002-07-11 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション

Also Published As

Publication number Publication date
HUP0402619A3 (en) 2008-04-28
NO20042904L (no) 2004-09-07
TW200300672A (en) 2003-06-16
ES2295435T3 (es) 2008-04-16
IL161989A0 (en) 2005-11-20
CZ2004709A3 (cs) 2004-10-13
CN1713900A (zh) 2005-12-28
DE60223718D1 (de) 2008-01-03
WO2003049724A1 (en) 2003-06-19
AU2002352625A1 (en) 2003-06-23
EP1458368B1 (en) 2007-11-21
US20050009925A1 (en) 2005-01-13
HRPK20040528B3 (en) 2006-03-31
KR20040066895A (ko) 2004-07-27
JP2005517647A (ja) 2005-06-16
HUP0402619A2 (hu) 2005-03-29
CA2467802A1 (en) 2003-06-19
CO5590907A2 (es) 2005-12-30
DE60223718T2 (de) 2008-10-30
SK2442004A3 (en) 2004-12-01
NZ532065A (en) 2007-03-30
EA200400793A1 (ru) 2004-10-28
ZA200404274B (en) 2005-09-13
MXPA04005716A (es) 2004-12-06
HRP20040528A2 (en) 2004-10-31
ECSP045145A (es) 2004-07-23
EP1458368A1 (en) 2004-09-22
MY136367A (en) 2008-09-30
PL369311A1 (en) 2005-04-18

Similar Documents

Publication Publication Date Title
AR032086A1 (es) Combinaciones de farmacos
BR0213581A (pt) Uso de um inibidor de recaptação de norepinefrina seletivo
ECSP17046065A (es) Formas cristalinas de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolhidrocloruro (solicitud divisional)
BR0113669A (pt) Inibidores da desacetilase
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
UY28348A1 (es) Compuestos novedosos
BR0317715A (pt) Composições e processos de uso de collajolie
BR0215405A (pt) Composições e processos de uso de collajolie
ECSP055525A (es) Inhibidores de cinasas de tirosina
AR026163A1 (es) Utilizacion de retigabina para el tratamiento de dolores neuropaticos
BRPI0412684A (pt) compostos ppar-ativos
NO20053088L (no) Farmasoytisk preparat inneholdende en beta-3-adrenoseptoragonist og en serotonin og/eller norepinefrin-gjenopptakelsesinhibitor og anvendelse av nevnte preparat for behandling av blaeredysfunksjon.
PT1339399E (pt) Combinacoes de drogas (e.g., clorpromazina e pentamidina) para o tratamento de desordens neoplasicas
PT1259512E (pt) Compostos de pteridin para o tratamento da psoriase
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
BR0312850B1 (pt) processo para espessar uma composiÇço condicionadora de cabelo À base de Água e/ou àleo, uso de um copolÍmero, e composiÇço para tratamento pessoal À base de àleo/Água.
BR0210650A (pt) Tablete, e, uso do mesmo
AR047553A1 (es) La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina
HRP20031057B1 (hr) Tableta koja sadrži cetirizin i pseudoefedrin
UY27461A1 (es) Formas pseudopolimorficas de cardevilol.
EP1569634B8 (en) Use of a ppar-alpha agonist and metformin for the treatment of obesity
UY26556A1 (es) Compuestos calcilíticos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.